Boehringer Ingelheim: Idiopathic Pulmonary Fibrosis trials
The registry lists 36 Idiopathic Pulmonary Fibrosis studies with Boehringer Ingelheim as lead sponsor. 1 are open to participants now and 26 have results posted.
Phase 1 1Phase 2 7Phase 3 5Phase 4 5No phase 18(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard TreatmentNot yet recruitingNCT07926321Phase 2
- A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisTerminatedNCT06360094Phase 2Results posted
- A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking NintedanibCompletedNCT06200714Results posted
- Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) PatientsCompletedNCT05870956Results posted
- Dose Reduction and Discontinuation With Anti-Fibrotic MedicationsCompletedNCT05779007Results posted
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Phase 3Results posted
- Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis PatientsCompletedNCT05022784Results posted
- Safety and Effectiveness of Nintedanib in Korean PatientsCompletedNCT04525547Results posted
- A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT04419506Phase 2Results posted
- A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are TakingCompletedNCT03958071Results posted
- Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03717012Phase 4Results posted
- Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With NintedanibCompletedNCT03710824Results posted
- Digital Auscultation Test - IPF Data CollectionCompletedNCT03503188Phase 4Results posted
- This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.CompletedNCT03422068Phase 1Results posted
- OASIS-IPF (Idiopathic Pulmonary Fibrosis) StudyCompletedNCT03386994Results posted
- Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in SpainCompletedNCT03281200Results posted
- Investigating Idiopathic Pulmonary Fibrosis in GreeceCompletedNCT03074149Results posted
- Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary FibrosisCompletedNCT03047031Results posted
- IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary FibrosisCompletedNCT02803580Results posted
- Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function ImpairmentCompletedNCT02802345Phase 3Results posted
- Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity ImpairmentCompletedNCT02788474Phase 4Results posted
- All-Case Surveillance of Ofev in Patients With IPF in JapanCompletedNCT02607722Results posted
- A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in CombinationCompletedNCT02606877Phase 4Results posted
- Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPFCompletedNCT02579603Phase 4Results posted
- Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01979952Phase 3Results posted
- Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary FibrosisCompletedNCT01619085Phase 3Results posted
- Safety and PK Study of BIBF 1120 in Japanese Patients With IPFCompletedNCT01136174Phase 2Results posted
- Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World StudyCompletedNCT07743996
- A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard TreatmentActive, not recruitingNCT07036523Phase 2
- Real-life-persistence to Antifibrotic TreatmentsCompletedNCT06485635
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Phase 2
- A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodCompletedNCT06241560Phase 2
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Phase 3
- NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With NintedanibCompletedNCT04614441
- Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary FibrosisNo longer availableNCT02230982
- Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)Approved for marketingNCT02171156